Jose Manuel Jerez

Jose Manuel Jerez

Auto-generated profile, based on publicly available information

Jose Manuel Jerez

Department of Languages and Computer Science, School of Engineering, University of Malaga, 29016 Malaga, Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Artificial Intelligence in Medicine
Verified
Journal Article
Closed access
JJJosé M. Jerez
José M. Jerez
IMIgnacio Molina
Ignacio Molina
PGPedro J. García-Laencina
Pedro J. García-Laencina
EAEmilio Alba
Emilio Alba
NRNuria Ribelles
Nuria Ribelles
Leonardo FrancoLeonardo Franco
Leonardo Franco

1 January 2003 in Artificial Intelligence in Medicine
Verified
Journal Article
Closed access
JJJosé M. Jerez-Aragonés
José M. Jerez-Aragonés
JGJose Antonio Gomez-Ruiz
Jose Antonio Gomez-Ruiz
GRGonzalo Ramos-Jiménez
Gonzalo Ramos-Jiménez
JMJosé Muñoz-Pérez
José Muñoz-Pérez
EAEmilio Alba
Emilio Alba

22 October 2013 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
NRNuria Ribelles
Nuria Ribelles
LPLidia Perez-Villa
Lidia Perez-Villa
JJJose Manuel Jerez
Jose Manuel Jerez
BPBella Pajares
Bella Pajares
LVLuis Vicioso
Luis Vicioso
EAEmilio Alba
Emilio Alba
Introduction: Recurrence risk in breast cancer varies throughout the follow-up time. We examined if these changes are related to the level of expression of the proliferation pathway and intrinsic subtypes. Methods: Expression of estrogen and progesterone receptor, Ki-67, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR) and cytokeratin 5/6 (CK 5/6) was performed on tissue-microarrays constructed from a large and uniformly managed series of early breast cancer patients (N = 1,249). Subtype definitions by four biomarkers were as follows: luminal A (ER + and/or PR+, HER2-, Ki-67 <14), luminal B (ER + and/or PR+, HER2-, Ki-67 ≥14), HER2-enriched (any ER, any PR, HER2+, any Ki-67), triple-negative (ER-, PR-, HER2-, any Ki-67). Subtype definitions by six biomarkers were as follows: luminal A (ER + and/or PR+, HER2-, Ki-67 <14, any CK 5/6, any EGFR), luminal B (ER + and/or PR+, HER2-, Ki-67 ≥14, any CK 5/6, any EGFR), HER2-enriched (ER-, PR-, HER2+, any Ki-67, any CK 5/6, any EGFR), Luminal-HER2 (ER + and/or PR+, HER2+, any Ki-67, any CK 5/6, any EGFR), Basal-like (ER-, PR-, HER2-, any Ki-67, CK5/6+ and/or EGFR+), triple-negative nonbasal (ER-, PR-, HER2-, any Ki-67, CK 5/6-, EGFR-). Each four- or six-marker defined intrinsic subtype was divided in two groups, with Ki-67 <14% or with Ki-67 ≥14%. Recurrence hazard rate function was determined for each intrinsic subtype as a whole and according to Ki-67 value. Results: Luminal A displayed a slow risk increase, reaching its maximum after three years and then remained steady. Luminal B presented most of its relapses during the first five years. HER2-enriched tumors show a peak of recurrence nearly twenty months post-surgery, with a greater risk in Ki-67 ≥14%. However a second peak occurred at 72 months but the risk magnitude was greater in Ki-67 <14%. Triple negative tumors with low proliferation rate display a smooth risk curve, but with Ki-67 ≥14% show sharp peak at nearly 18 months. Conclusions: Each intrinsic subtype has a particular pattern of relapses over time which change depending on the level of activation of the proliferation pathway assessed by Ki-67. These findings could have clinical implications both on adjuvant treatment trial design and on the recommendations concerning the surveillance of patients.

5 April 2007 in Biological Cybernetics
Verified
Journal Article
Closed access
PDF file
Leonardo FrancoLeonardo Franco
Leonardo Franco
EREdmund T Rolls
Edmund T Rolls
NANikolaos C. Aggelopoulos
Nikolaos C. Aggelopoulos
JJJose M. Jerez
Jose M. Jerez

12 August 2015 in IEEE Transactions on Neural Networks and Learning Systems
Verified
Journal Article
Closed access
FOFrancisco Ortega-Zamorano
Francisco Ortega-Zamorano
JJJose M. Jerez
Jose M. Jerez
Daniel Urda MuñozDaniel Urda Muñoz
Daniel Urda Muñoz
RBRafael Marcos Luque Baena
Rafael Marcos Luque Baena
Leonardo FrancoLeonardo Franco
Leonardo Franco
The well-known backpropagation learning algorithm is implemented in a field-programmable gate array (FPGA) board and a microcontroller, focusing in obtaining efficient implementations in terms of a resource usage and computational speed. The algorithm was implemented in both cases using a training/validation/testing scheme in order to avoid overfitting problems. For the case of the FPGA implementation, a new neuron representation that reduces drastically the resource usage was introduced by combining the input and first hidden layer units in a single module. Further, a time-division multiplexing scheme was implemented for carrying out product computations taking advantage of the built-in digital signal processor cores. In both implementations, the floating-point data type representation normally used in a personal computer (PC) has been changed to a more efficient one based on a fixed-point scheme, reducing system memory variable usage and leading to an increase in computation speed. The results show that the modifications proposed produced a clear increase in computation speed in comparison with the standard PC-based implementation, demonstrating the usefulness of the intrinsic parallelism of FPGAs in neurocomputational tasks and the suitability of both implementations of the algorithm for its application to the real world problems.

14 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LPLuis G. Pérez-Rivas
Luis G. Pérez-Rivas
JJJosé M. Jerez
José M. Jerez
RCRosario Carmona
Rosario Carmona
VLVanessa de Luque
Vanessa de Luque
LVLuis Vicioso
Luis Vicioso
JLJosé Lozano
José Lozano
Recurrent breast cancer occurring after the initial treatment is associated with poor outcome. A bimodal relapse pattern after surgery for primary tumor has been described with peaks of early and late recurrence occurring at about 2 and 5 years, respectively. Although several clinical and pathological features have been used to discriminate between low- and high-risk patients, the identification of molecular biomarkers with prognostic value remains an unmet need in the current management of breast cancer. Using microarray-based technology, we have performed a microRNA expression analysis in 71 primary breast tumors from patients that either remained disease-free at 5 years post-surgery (group A) or developed early (group B) or late (group C) recurrence. Unsupervised hierarchical clustering of microRNA expression data segregated tumors in two groups, mainly corresponding to patients with early recurrence and those with no recurrence. Microarray data analysis and RT-qPCR validation led to the identification of a set of 5 microRNAs (the 5-miRNA signature) differentially expressed between these two groups: miR-149, miR-10a, miR-20b, miR-30a-3p and miR-342-5p. All five microRNAs were down-regulated in tumors from patients with early recurrence. We show here that the 5-miRNA signature defines a high-risk group of patients with shorter relapse-free survival and has predictive value to discriminate non-relapsing versus early-relapsing patients (AUC = 0.993, p-value<0.05). Network analysis based on miRNA-target interactions curated by public databases suggests that down-regulation of the 5-miRNA signature in the subset of early-relapsing tumors would result in an overall increased proliferative and angiogenic capacity. In summary, we have identified a set of recurrence-related microRNAs with potential prognostic value to identify patients who will likely develop metastasis early after primary breast surgery.